In a study presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), higher levels of IL6ST were correlated with active ER signaling and predicted clinical response to neoadjuvant letrozole in ER+/HER2+ EBCs. The gene discussed is ERBB2; the disease is breast cancer.